{"id":"W2948813200","doi":"10.1186/s13075-019-1917-8","title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry","year":2019,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Osteoporosis Canada; Montreal Clinical Research Institute","funders":"UCB; Sandoz; Celgene; Roche; Novartis; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AbbVie; Sanofi; Merck","keywords":"Abatacept; Golimumab; Medicine; Etanercept; Adalimumab; Infliximab; Certolizumab pegol; Rheumatoid arthritis; Discontinuation; Internal medicine; Hazard ratio; Persistence (discontinuity); Proportional hazards model; Tumor necrosis factor alpha; Confidence interval; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01756294,0.0001993545,0.0008964028,0.002108066,0.0004075632,0.001825156,0.00101283,0.0006004663,0.0008413578],"category_scores_gemma":[0.03584734,0.0003060327,0.001032616,0.003625218,0.000552922,0.001762095,0.001330039,0.0009133575,0.0002935718],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001229017,"about_ca_system_score_gemma":0.001861864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009308768,"about_ca_topic_score_gemma":0.005961908,"domain_scores_codex":[0.9847233,0.005269142,0.003894405,0.001675208,0.003754693,0.0006833469],"domain_scores_gemma":[0.930778,0.02210845,0.03563918,0.004374512,0.005281616,0.001818324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004651778,0.00005159251,0.9939674,0.00005572573,0.000167561,0.00006425097,0.0003964729,0.0000904109,0.00005796758,0.00004204245,0.0003106093,0.004330822],"study_design_scores_gemma":[0.0000736615,0.000297932,0.9957587,0.00008153018,0.0002210995,0.0005856384,0.0006522875,0.0007454776,0.0002104791,0.0000411701,0.001308406,0.0000236568],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916828,0.002429964,0.0004948974,0.0002276397,0.0000099075,0.00004682001,0.004412767,0.00001880292,0.0006762671],"genre_scores_gemma":[0.9935435,0.0007832421,0.000383547,0.00006893897,0.00002101193,0.00005416064,0.004988644,0.00001080643,0.0001461189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01756294,"threshold_uncertainty_score":0.09288281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1015715077618527,"score_gpt":0.3879436399079944,"score_spread":0.2863721321461417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}